- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01294748
Clinical Investigation of the MiStent Drug Eluting Stent (DES) in Coronary Artery Disease (DESSOLVE-II)
December 15, 2016 updated by: Micell Technologies
Clinical Investigation of a DES (MiStent™ System) With Sirolimus and a Bioabsorbable Polymer for the Treatment of Patients With De Novo Lesions in Native Coronary Arteries.
The DESSOLVE II clinical trial is to assess the safety and performance of the sirolimus-eluting MiStent for the treatment for improving coronary luminal diameter in patients with symptomatic ischemic heart disease due to discrete de novo lesions in the native coronary arteries.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
The DESSOLVE II clinical trial is to assess the safety and performance of the sirolimus-eluting MiStent as compared to the Endeavor DES for the treatment for improving coronary luminal diameter in patients with symptomatic ischemic heart disease due to discrete de novo lesions in the native coronary arteries.
Study Type
Interventional
Enrollment (Actual)
184
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Aalst, Belgium
- Cardiovascular Center
-
Antwerp, Belgium
- Antwerp Hospital, ZNA Middelheim
-
Brussels, Belgium
- Brussels University Hospital
-
Genk, Belgium
- Ziekenhuis Oost-Limburg
-
Hasselt, Belgium
- Virga Jesse Ziekenhuis
-
Leuven, Belgium
- KUL Cardiology Gasthuisberg
-
-
-
-
-
Massy, France
- Jacques Cartier Hospital
-
Quincy, France
- Claude Galien Hospital
-
Toulouse, France
- Clinique Pasteur
-
-
-
-
-
Amsterdam, Netherlands
- OLV
-
Nieuwegein, Netherlands
- St. Antonius Ziekenhuis
-
Tilburg, Netherlands
- TweeSteden Ziekenhuis
-
Utrecht, Netherlands
- UMC Utrecht
-
Zwolle, Netherlands
- Hospital Weezenlanden
-
-
-
-
-
Auckland, New Zealand
- Auckland City Hospital
-
Auckland, New Zealand
- Mercy Angiography Unit
-
Christchurch, New Zealand
- Christchurch Hospital
-
Dunedin, New Zealand
- Dunedin Hospital
-
Wellington, New Zealand
- Wellington Hospital
-
-
-
-
-
Goteborg, Sweden
- Sahlgrenska University Hospital
-
Orebro, Sweden
- Orebro University Hospital
-
-
-
-
-
Brighton, United Kingdom
- Royal Sussex Hosp
-
Cambridge, United Kingdom
- Papworth Hospital
-
London, United Kingdom
- Royal Brompton
-
London, United Kingdom
- Guy's & St. Thomas'
-
Manchester, United Kingdom
- University Hospital South Manchester
-
Norwich, United Kingdom
- Norfolk/Norwich UHosp
-
Southampton, United Kingdom
- Southampton UHT
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 85 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Age ≥18 and ≤85 years;
- Stable/unstable angina pectoris (Class I-IV), documented ischemia/silent ischemia;
- Planned single, de novo, types A, B1 or B2 coronary lesions;
- Target lesion located in a native coronary artery;
- Target lesion in vessel ranging from 2.5 to 3.5 mm amenable to treatment (coverage) with a 30 mm long stent;
- Target lesion with >50% diameter stenosis;
- Recent Q-wave (>72 hours) or non-Q-wave myocardial infarction;
- Patients eligible for PCI;
- Candidate for CABG ;
- A patient may have one additional critical non-target lesion.
- Patient capable of providing informed consent and is willing to comply with all study requirements.
Exclusion Criteria:
- Female patients of childbearing potential who do not have a confirmed negative pregnancy test at baseline and are not on some form of birth control;
- Recent Q-wave MI < 72 hours prior to the index procedure.
- Recent Q- or non-Q-wave MI with still elevated levels of cardiac markers (e.g. CK; and CK-MB if the CK is elevated);
- LVEF <30% (within the previous 6-months);
- Patients in cardiogenic shock;
- CVA or TIA within the past 6 months;
- Active GI bleeding within past 3 months;
- Any prior anaphylactic reaction to contrast agents;
- Chemotherapy within 30-days before or after the index procedure;
- Receiving oral or intravenous immunosuppressive therapy or has known life-limiting immunosuppressive or autoimmune disease;
- Renal dysfunction (creatinine > 2.0 mg/dL or 177 µmol/L);
- Platelet count <100,000 cells/mm³ or >700,000 cells/mm³;
- White blood cell count <3,000 cells/mm3;
- Hepatic disease;
- Heart transplant recipient;
- Known contraindication to DAPT;
- Known hypersensitivity to sirolimus, cobalt-chromium, or to medications such as aspirin, heparin and Angiomax (bivalirudin), and all three of the following: clopidogrel bisulfate (Plavix), ticlopidine (Ticlid), and Prasugrel (Effient);
- Life expectancy less than 12 months;
- Any major medical condition that may interfere with participation in this study;
- Patient is currently participating in an investigational drug or another device study and has not completed the follow-up to the primary endpoint, or the patient is planning on participating prior to completing 12-months follow-up;
- Target vessel has been treated within 10 mm proximal or distal to target lesion with any type of PCI or within a year prior to index procedure;
- Planned or actual target vessel(s) treatment with an unapproved device, directional or rotational coronary atherectomy, laser, cutting balloon, or transluminal extraction catheter prior to stent placement;
- Patient previously treated at any time with brachytherapy;
- Planned coronary angioplasty or CABG in the first 9 months after the index procedure or any other planned intervention within 30-days post index procedure;
- Prior PCI of a non-target vessel must be at least 14 days prior to study enrollment;
- The intent to direct stent the target lesion;
Angiographic Exclusion Criteria:
- In-stent restenotic target lesion;
- In-stent restenotic target lesion;
- More than one lesion requiring treatment in the target vessel);
- Target vessel diameter <2.5 mm or >3.5 mm;
- Long target lesion not amenable to treatment with up to a 30 mm long stent;
- Left main critical disease (≥50% DS);
- Target lesion is located in a surgical bypass graft;
- Total target vessel occlusion (TIMI flow grade 0-1);
- Target lesion ostial location;
- Target lesion at bifurcation involving side branch >2.5 mm or lateral branch that also requires stenting;
- Calcified target lesion that anticipates unsuccessful/impracticable predilation;
- Target vessel with excessive tortuosity or proximal angulation;
- Thrombus present in target vessel;
- More than one non-target critical lesion;
Non-target lesion to be treated during the index procedure meets any of the following criteria:
- Located within the target vessel;
- Located within a bypass graft ;
- Left main location;
- Chronic total occlusion
- Involves a complex bifurcation.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: MiStent DES
The MiStent SES is a sirolimus-eluting absorbable polymer stent for coronary artery revascularization.
|
The MiStent is a device/drug combination comprised of two components; a stent and a drug product (sirolimus within an absorbable polymer coating).
|
Active Comparator: Endeavor DES
The Endeavor DES is an everolimus-eluting durable polymer stent for coronary artery revascularization.
|
The Endeavor is a device/drug combination comprised of two components; a stent and a drug product (everolimus within a durable polymer coating).
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
In-Stent Late Lumen Loss
Time Frame: 9 months
|
Measured by the angiographic core laboratory as the difference between the post-procedure MLD in the treated segment (stented region) minus the MLD in the same region at follow-up
|
9 months
|
Major Adverse Cardiac Events (MACE)
Time Frame: 9 months
|
Defined as death, MI (Qwave and non-Q-wave) and TVR at 9 months post-procedure.
Assessed on all patients with adequate follow-up at 270 days.
|
9 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Device Success
Time Frame: 8 hours
|
Achievement of a final in-stent residual diameter stenosis of <50% (by QCA), using the assigned device only.
|
8 hours
|
Lesion Success
Time Frame: 8 hours
|
Achievement of a final in-stent residual diameter stenosis of <50% (by QCA) using any percutaneous method.
|
8 hours
|
Procedural Success
Time Frame: 8 hours
|
Achievement of a final in-stent residual diameter stenosis of <50% (by QCA) using the assigned device (including any adjunctive devices) without cardiac death, MI or repeat revascularization of the target lesion pre-hospital discharge.
|
8 hours
|
Total Mortality
Time Frame: 9-months
|
9-months
|
|
Total Myocardial Infarct (MI)
Time Frame: 9-months
|
|
9-months
|
Clinically-driven Target Lesion Revascularization (TVR)
Time Frame: 9-months
|
TVR is defined as any repeat percutaneous intervention or surgical bypass of any segment of the target vessel (main branch or side branch).
The target vessel is defined as the entire major coronary vessel proximal and distal to the target lesion, which includes upstream and downstream branches, and the target lesion itself.
|
9-months
|
Target Vessel Failure (TVF)
Time Frame: 9-months
|
Composite endpoint of cardiac death, target-vessel myocardial infarction (Q wave or non-Q wave), and clinically indicated target vessel revascularization
|
9-months
|
Target Lesion Failure (TLF)
Time Frame: 9-months
|
Composite endpoint of cardiac death, target-lesion myocardial infarction (Q wave or non-Q wave), and clinically indicated target lesion revascularization
|
9-months
|
Stent Thrombosis (Definite/Probable)
Time Frame: 9-months
|
The presence of an intracoronary thrombus that originates in the stent or in the segments 5 mm proximal or distal to the stent post-procedure
|
9-months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
General Publications
- Rusinaru D, Vrolix M, Verheye S, Chowdhary S, Schoors D, Di Mario C, Desmet W, Donohoe DJ, Ormiston JA, Knape C, Bezerra H, Lansky A, Wijns W; DESSOLVE II Investigators. Bioabsorbable polymer-coated sirolimus-eluting stent implantation preserves coronary vasomotion: A DESSOLVE II trial sub-study. Catheter Cardiovasc Interv. 2015 Dec 1;86(7):1141-50. doi: 10.1002/ccd.25610. Epub 2015 Sep 22.
- Wijns W, Vrolix M, Verheye S, Schoors D, Slagboom T, Gosselink M, Benit E, Donohoe D, Knape C, Attizzani GF, Lansky AJ, Ormiston J; DESSOLVE II Investigators. Randomised study of a bioabsorbable polymer-coated sirolimus-eluting stent: results of the DESSOLVE II trial. EuroIntervention. 2015 Apr;10(12):1383-90. doi: 10.4244/EIJY14M05_03.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
February 1, 2011
Primary Completion (Actual)
June 1, 2012
Study Completion (Actual)
August 1, 2016
Study Registration Dates
First Submitted
February 10, 2011
First Submitted That Met QC Criteria
February 10, 2011
First Posted (Estimate)
February 11, 2011
Study Record Updates
Last Update Posted (Estimate)
February 8, 2017
Last Update Submitted That Met QC Criteria
December 15, 2016
Last Verified
December 1, 2016
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- MIS-CEM-2010-02
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Coronary Artery Disease
-
Elixir Medical CorporationIstituto Clinico HumanitasActive, not recruitingCoronary Artery Disease | Chronic Total Occlusion of Coronary Artery | Multi Vessel Coronary Artery Disease | Bifurcation of Coronary Artery | Long Lesions Coronary Artery DiseaseItaly
-
Fundación EPICActive, not recruitingCoronary Artery Disease | Left Main Coronary Artery Disease | Left Main Coronary Artery Stenosis | Restenosis, CoronarySpain
-
Peking Union Medical College HospitalNot yet recruitingCoronary Artery Disease | Inflammation | Coronary Artery Disease Progression | Coronary Artery Stenosis | Coronary Artery Restenosis | Inflammatory Disease | Inflammation VascularChina
-
Peking Union Medical College HospitalRecruitingCoronary Artery Disease | Inflammation | Coronary Artery Disease Progression | Coronary Artery Stenosis | Coronary Artery Restenosis | Inflammatory Disease | Inflammation VascularChina
-
IGLESIAS Juan FernandoUniversity of BernNot yet recruiting
-
National Institutes of Health Clinical Center (CC)National Heart, Lung, and Blood Institute (NHLBI)CompletedCoronary Arteriosclerosis | Coronary Artery Disease (CAD) | Obstructive Coronary Artery DiseaseUnited States
-
Barts & The London NHS TrustImperial College London; Brunel UniversityNot yet recruitingCORONARY ARTERY DISEASE
-
Fundación EPICRecruitingCoronary Artery Disease | Coronary Disease | Coronary Occlusion | Left Main Coronary Artery Disease | Coronary Artery StenosisSpain
-
Abbott Medical DevicesCompletedCoronary Artery Disease | Coronary Disease | Coronary Occlusion | Chronic Total Occlusion of Coronary Artery | Coronary Restenosis | Coronary Artery Stenosis | Coronary Artery RestenosisBelgium
-
China National Center for Cardiovascular DiseasesRecruitingLeft Main Coronary Artery DiseaseChina
Clinical Trials on MiStent DES
-
ECRI bvMicell Technologies; StentysCompletedCoronary StenosisFrance, Germany, Netherlands, Poland
-
Boston Scientific CorporationLabcoat, Ltd.Completed
-
Micell TechnologiesYale Cardiovascular Research Group; North American Science Associates Inc.; Baim...Not yet recruiting
-
Micell TechnologiesCompletedFirst-In-Human Trial of the MiStent Drug-Eluting Stent (DES) in Coronary Artery Disease (DESSOLVE-I)Coronary Artery DiseaseBelgium, Australia, New Zealand
-
Micell TechnologiesHefei Life Science Medical Instruments Co. Ltd.; Giant Med-Pharma Services... and other collaboratorsUnknownCoronary Heart DiseaseChina
-
Azienda Ospedaliera Città della Salute e della...RecruitingCoronary Artery Disease | Chronic Total Occlusion of Coronary Artery | Left Main Coronary Artery Disease | Coronary Stenosis | Stent RestenosisItaly
-
Fondazione Evidence per Attività e Ricerche Cardiovascolari...Mediolanum Cardio ResearchCompletedMyocardial Infarction
-
Henan Institute of Cardiovascular EpidemiologyRecruiting
-
Norfolk and Norwich University Hospitals NHS Foundation...University of East AngliaRecruiting
-
Istituto Clinico Sant'AmbrogioUnknownCoronary Artery DiseaseItaly